Literature DB >> 8486956

Immunogenicity of Haemophilus influenzae type b conjugate vaccine in children with congenital asplenia.

S A Webber1, G G Sandor, M W Patterson, L A Mitchell, D Scheifele, J J Ochnio, P H McVerry.   

Abstract

The immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines in congenitally asplenic children is unknown. The short-term immunogenicity of the H. influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine was therefore assessed in 10 children with congenital asplenia by measuring antipolyribosyl-ribitol phosphate antibody titers. An excellent antibody response was seen in 9 children (mean geometric titer in responders after immunization 44.7 micrograms/mL; range, 2.59-402). The remaining child responded to a booster dose. Further studies are required to assess whether H. influenzae type b conjugate vaccines are immunogenic in infancy in the presence of congenital asplenia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486956     DOI: 10.1093/infdis/167.5.1210

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants.

Authors:  D W Scheifele; G L Bjornson; W G Meekison; R Guasparini; L A Mitchell
Journal:  Can J Infect Dis       Date:  1994-03

2.  Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides.

Authors:  M A Breukels; A Zandvoort; G P van Den Dobbelsteen; A van Den Muijsenberg; M E Lodewijk; M Beurret; P A Klok; W Timens; G T Rijkers
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

3.  Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.

Authors:  Paul Balmer; Michelle Falconer; Paula McDonald; Nick Andrews; Emily Fuller; Christine Riley; Edward Kaczmarski; Raymond Borrow
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.